359 related articles for article (PubMed ID: 34771535)
21. A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma.
Xia Y; Li X; Jiang N; Wei X
MedComm (2020); 2023 Dec; 4(6):e424. PubMed ID: 37929016
[TBL] [Abstract][Full Text] [Related]
22. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib.
Charalambous A; Schwarzbich MA; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():133-168. PubMed ID: 30069629
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Lionakis MS; Dunleavy K; Roschewski M; Widemann BC; Butman JA; Schmitz R; Yang Y; Cole DE; Melani C; Higham CS; Desai JV; Ceribelli M; Chen L; Thomas CJ; Little RF; Gea-Banacloche J; Bhaumik S; Stetler-Stevenson M; Pittaluga S; Jaffe ES; Heiss J; Lucas N; Steinberg SM; Staudt LM; Wilson WH
Cancer Cell; 2017 Jun; 31(6):833-843.e5. PubMed ID: 28552327
[TBL] [Abstract][Full Text] [Related]
26. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
Hu BN; Yang X; Yuan YP; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
[TBL] [Abstract][Full Text] [Related]
27. Current and emerging therapies for primary central nervous system lymphoma.
Yuan Y; Ding T; Wang S; Chen H; Mao Y; Chen T
Biomark Res; 2021 May; 9(1):32. PubMed ID: 33957995
[TBL] [Abstract][Full Text] [Related]
28. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.
Jiménez I; Carabia J; Bobillo S; Palacio C; Abrisqueta P; Pagès C; Nieto JC; Castellví J; Martínez-Ricarte F; Escoda L; Perla C; Céspedes Torrez DH; Boix J; Purroy N; Puigdefàbregas L; Seoane J; Bosch F; Crespo M
J Neurooncol; 2020 Aug; 149(1):13-25. PubMed ID: 32691208
[TBL] [Abstract][Full Text] [Related]
29. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
30. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
[TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon.
Lino-Silva LS; Martínez-Villavicencio SB; Rivera-Moncada LF
World J Clin Oncol; 2024 May; 15(5):587-590. PubMed ID: 38835851
[TBL] [Abstract][Full Text] [Related]
32. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
[TBL] [Abstract][Full Text] [Related]
33. Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Illerhaus G; Schorb E; Kasenda B
Blood; 2018 Aug; 132(7):681-688. PubMed ID: 29986908
[TBL] [Abstract][Full Text] [Related]
34. Primary central nervous system lymphoma.
Löw S; Han CH; Batchelor TT
Ther Adv Neurol Disord; 2018; 11():1756286418793562. PubMed ID: 30305848
[TBL] [Abstract][Full Text] [Related]
35. Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy.
Du S; Bota D; Kong XT
Neurol Int; 2022 Jun; 14(3):574-580. PubMed ID: 35893281
[TBL] [Abstract][Full Text] [Related]
36. Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.
Schaff LR; Ambady P; Doolittle ND; Grommes C
Ann Lymphoma; 2021 Mar; 5():. PubMed ID: 33912868
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
[TBL] [Abstract][Full Text] [Related]
38. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
Elife; 2020 Nov; 9():. PubMed ID: 33226337
[TBL] [Abstract][Full Text] [Related]
39. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
40. Primary central nervous system lymphoma - ocular variant: an interdisciplinary review on management.
Raval V; Binkley E; Aronow ME; Valenzuela J; Peereboom DM; Singh AD
Surv Ophthalmol; 2021; 66(6):1009-1020. PubMed ID: 33762182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
